The Overview
ArriVent BioPharma announced that its Phase 3 FURVENT trial (NCT05607550) evaluating firmonertinib monotherapy in previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations did not meet its primary endpoint of progression-free survival (PFS) by blinded independent central review (BICR). The firmonertinib 240mg arm showed a median PFS of 11.0 months compared to 9.5 months for the control arm (HR 0.75, p=0.0654), which was not statistically significant. Clinical benefit was observed in secondary endpoints, including PFS by investigator’s assessment and confirmed objective response rate by BICR (60% for 240mg vs 33% for control). A trend toward improved overall survival was also noted, though data is not yet mature. The safety profile was consistent with previous studies, with no new signals identified.
Knolens Analysis
At a Glance
| Indication | locally advanced or metastatic non-squamous non-small cell lung cancer harboring EGFR exon 20 insertion mutations |
| Drug | firmonertinib |
| Mechanism of Action | EGFR inhibitor |
| Company | ArriVent BioPharma, Inc. |
| Trial Phase | Phase 3 |
| Trial Acronym | FURVENT |
| NCT ID | NCT05607550 |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Negative |
| Therapeutic Area | Oncology |
| Primary Endpoint | Progression Free Survival (PFS) by BICR per RECIST 1.1 |
| Secondary Endpoints | Overall Survival (OS), PFS by investigator’s assessment, confirmed objective response rate by BICR, brain-specific CNS overall response rate (CNS-ORR), CNS-PFS by mRECIST |
| Comparator | platinum-based chemotherapy with pemetrexed |
| Dosage | firmonertinib 160 mg, firmonertinib 240 mg (once-daily) |
| Patient Population Size | 398 patients |
| PFS (BICR) 240mg | 11.0 months |
| HR (95% CI) 240mg vs Control | 0.75 (0.55, 1.02) |
| Confirmed ORR (BICR) 240mg | 60% |
| Regulatory Designation | U.S. FDA Breakthrough Therapy Designation, U.S. FDA Orphan Drug Designation |
| Treatment-Related Adverse Events Grade ≥ 3 | 26% (firmonertinib 240mg), 22% (firmonertinib 160mg), 40% (control arm) |
ArriVent's Firmonertinib Misses Primary Endpoint in First-Line NSCLC Trial
ArriVent BioPharma announced that its Phase 3 FURVENT trial (NCT05607550) evaluating firmonertinib monotherapy in previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations did not meet its primary endpoint of progression-free survival (PFS) by blinded independent central review (BICR). The firmonertinib 240mg arm showed a median PFS of 11.0 months compared to 9.5 months for the control arm (HR 0.75, p=0.0654), which was not statistically significant. Clinical benefit was observed in secondary endpoints, including PFS by investigator’s assessment and confirmed objective response rate by BICR (60% for 240mg vs 33% for control). A trend toward improved overall survival was also noted, though data is not yet mature. The safety profile was consistent with previous studies, with no new signals identified.
- The Phase 3 FURVENT trial, involving 398 patients, failed to achieve its primary endpoint of progression-free survival (PFS) as assessed by blinded independent central review (BICR). The firmonertinib 240mg arm demonstrated a median PFS of 11.0 months, compared to 9.5 months in the platinum-based chemotherapy control arm, with a hazard ratio of 0.75 (95% CI: 0.55, 1.02) and a p-value of 0.0654, indicating it did not reach statistical significance.
- Despite the primary endpoint miss, the trial showed clinical benefit in several secondary endpoints. Investigator-assessed PFS was 11.1 months for firmonertinib 240mg versus 7.1 months for control (HR 0.61). The confirmed objective response rate (ORR) by BICR was 60% for the 240mg dose compared to 33% for the control arm. Additionally, a trend toward an improvement in overall survival was observed, although this data is not yet mature.
- Firmonertinib maintained a safety profile consistent with prior clinical studies, with no new safety signals identified in the FURVENT trial. Treatment-emergent adverse events (TEAE) Grade ≥ 3 were 52% for firmonertinib 240mg, 53% for 160mg, and 55% for the control arm. Treatment-related adverse events (TRAE) Grade ≥ 3 were lower in the firmonertinib arms (26% for 240mg, 22% for 160mg) compared to the control arm (40%).
Frequently Asked Questions
Why are EGFR exon 20 insertion mutations considered a distinct challenge in NSCLC treatment?
EGFR exon 20 insertion mutations represent a unique subset of NSCLC that historically responds poorly to standard first- and second-generation EGFR tyrosine kinase inhibitors. These insertions alter the ATP-binding pocket of the EGFR kinase domain in a way that reduces drug binding affinity for many conventional TKIs. This structural difference necessitates the development of highly specific inhibitors designed to overcome this inherent resistance mechanism.
What is the mechanism of action of firmonertinib in targeting EGFR exon 20 insertion mutations?
Firmonertinib is a third-generation EGFR tyrosine kinase inhibitor specifically designed to target EGFR exon 20 insertion mutations. It covalently binds to the EGFR kinase domain, effectively inhibiting the constitutively active mutant receptor. This targeted inhibition aims to block downstream signaling pathways crucial for tumor growth and survival in patients with these specific mutations.
How does firmonertinib fit into the evolving treatment paradigm for EGFR exon 20 insertion NSCLC?
Firmonertinib offers a targeted therapeutic option for a patient population with significant unmet medical needs. Its development represents a crucial advancement in precision oncology for NSCLC, providing a dedicated treatment strategy where previous EGFR TKIs had limited efficacy. This drug contributes to a more personalized approach, improving outcomes for patients with this challenging mutation.
What diagnostic approaches are crucial for identifying EGFR exon 20 insertion mutations in NSCLC patients?
Comprehensive genomic profiling, particularly next-generation sequencing (NGS), is essential for accurately identifying EGFR exon 20 insertion mutations. These mutations can be complex and diverse, requiring sensitive and specific molecular testing methods to distinguish them from more common EGFR mutations. Precise identification ensures patients can be considered for appropriate targeted therapies.
Contact Us
📍
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
✉️
For General Inquiry
info@pienomial.com
